NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Gland Pharma Reappoints Ms. Naina Lal Kidwai as Independent Director for 5-Year Term
Gland Pharma has received shareholder approval to reappoint Ms. Naina Lal Kidwai as an Independent Director for a second five-year term, effective from May 17, 2026, to May 16, 2031. Ms. Kidwai is a highly distinguished professional, currently serving as Chairman of Rothschild & Co India and having previously chaired HSBC India. The reappointment, conducted via postal ballot, also includes approval for remuneration via commission on profits. This move ensures continuity in the company's high-level governance and strategic oversight by a veteran of the Indian financial and corporate sector.
முக்கிய அம்சங்கள்
Reappointed for a second consecutive term of 5 years starting May 17, 2026, until May 16, 2031.Shareholders approved the reappointment and payment of commission on profits through a postal ballot.Ms. Kidwai brings extensive experience as the former Chairman of HSBC India and current Chairman of Rothschild & Co India.She is a recipient of the Padma Shri and holds an MBA from Harvard Business School, serving on multiple global boards like Holcim and Biocon.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for corporate governance, as it retains a highly respected and experienced independent voice on the board. No immediate portfolio action is required based on this announcement.
Gland Pharma Limited has successfully passed a special resolution via postal ballot to reappoint Ms. Naina Lal Kidwai as an Independent Director. The resolution also approved the payment of commission on profits as part of her remuneration package. While the resolution passed with an overall majority of 94.18%, there was notable dissent from public institutional investors, with 13.58% of their votes cast against the proposal. Promoters remained fully supportive, voting 100% in favor of the reappointment.
முக்கிய அம்சங்கள்
Special resolution for the reappointment of Ms. Naina Lal Kidwai as Independent Director passed with 94.18% of total votes.Total votes polled were 149,437,703, accounting for 90.70% of the total outstanding shares.Public institutional investors cast 8,694,537 votes (13.58%) against the resolution.Promoter group provided full support with 85,393,894 votes cast 100% in favor.The approval includes a provision for remuneration via commission on company profits.
👀 கவனிக்க வேண்டியவை
This is a routine governance matter ensuring board continuity; no immediate action is required. Investors should note the moderate institutional dissent regarding the remuneration structure but recognize that the board's leadership remains stable.
Gland Pharma Re-appoints Naina Lal Kidwai as Independent Director for 5-Year Term
Gland Pharma's Board has approved the re-appointment of Ms. Naina Lal Kidwai as an Independent Director for a second five-year term. This term will commence on May 17, 2026, and extend until May 16, 2031, subject to shareholder approval via postal ballot. Ms. Kidwai is a highly distinguished professional, currently serving as Chairman of Rothschild & Co India and holding a Padma Shri award. Her continued presence on the board is expected to provide strong corporate governance and strategic oversight for the company.
முக்கிய அம்சங்கள்
Re-appointment of Ms. Naina Lal Kidwai for a second term of 5 consecutive years.New term effective from May 17, 2026, through May 16, 2031.Shareholder approval to be sought via postal ballot and e-voting as per SEBI regulations.Ms. Kidwai brings extensive experience as former Chairman of HSBC India and current Chairman of Rothschild & Co India.
👀 கவனிக்க வேண்டியவை
No immediate action is required as this is a routine governance matter. The retention of a high-profile independent director like Ms. Kidwai is a positive signal for long-term corporate governance and board stability.
Gland Pharma has received tentative approval from the USFDA for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC), a generic version of Bausch & Lomb's Lumify. The product is indicated for the relief of eye redness and targets a US market segment valued at approximately USD 39 million for the twelve months ending September 2025. While the approval is tentative, it marks a significant step in expanding Gland's ophthalmic portfolio in the US market. The company will now await final approval to commence commercial production and distribution under its B2B model.
முக்கிய அம்சங்கள்
Received USFDA tentative approval for Brimonidine Tartrate Ophthalmic Solution, 0.025% (OTC).Product is bioequivalent to the reference drug Lumify, owned by Bausch & Lomb Inc.Target market size in the US is approximately USD 39 million as per IQVIA data for the year ending Sept 2025.The product is indicated for the relief of eye redness, strengthening Gland's ophthalmic segment.Approval aligns with Gland's strategy to expand its sterile injectable and ophthalmic footprint globally.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for Gland's R&D pipeline, though they should monitor the timeline for final approval and commercial launch. The relatively small market size of USD 39 million suggests this is an incremental rather than transformative addition to revenue.
Gland Pharma CEO Shyamakant Giri Resigns; Effective April 30, 2026
Gland Pharma Limited has announced the resignation of Mr. Shyamakant Giri from his role as Chief Executive Officer and Key Management Personnel. The resignation was submitted on February 24, 2026, and officially accepted by the Board of Directors on March 3, 2026. Mr. Giri will continue in his role until the close of business hours on April 30, 2026, providing a transition period of nearly two months. The departure is attributed to his decision to pursue new professional opportunities outside the company.
முக்கிய அம்சங்கள்
Mr. Shyamakant Giri to step down as CEO and KMP effective April 30, 2026.Resignation letter was dated February 24, 2026, and accepted by the Board on March 3, 2026.The company has a transition window of approximately 8 weeks to manage the leadership change.The departure is voluntary as the executive seeks to pursue new opportunities.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming announcements regarding a successor to ensure leadership continuity. While the notice period provides some stability, the appointment of a new CEO will be a critical factor for the stock's future performance.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Gland Pharma Appoints Dr. Jitendra Gangwal as VP of R&D to Lead Complex Product Development
Gland Pharma has appointed Dr. Jitendra Gangwal as Vice-President of Research and Development, effective February 18, 2026. Dr. Gangwal brings over 24 years of experience in pharmaceutical R&D, having previously held leadership roles at Dr. Reddy’s, Glenmark, and Alkem Laboratories. His track record includes the development of 55+ products and filing 10+ patents, specifically in complex delivery systems like liposomes and peptides. This strategic hire is intended to bolster Gland Pharma's pipeline of high-value complex injectables for regulated global markets.
முக்கிய அம்சங்கள்
Dr. Jitendra Gangwal appointed as VP (R&D) with over 24 years of pharmaceutical experience.Developed 55+ products across injections, ophthalmics, inhalation, and nasal routes.Filed 10+ patents and led multiple 505(b)(2) and ANDA filings in previous roles.Expertise in complex parenterals, nano-crystals, liposomes, and advanced polymer-based delivery systems.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive move to strengthen the company's core R&D capabilities. Monitor the pace of new ANDA filings and complex product approvals over the next 12-18 months to gauge the impact of this leadership change.
Gland Pharma Gets USFDA Approval for Zoledronic Acid Injection; US Market Size $6.7 Million
Gland Pharma has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Zoledronic Acid Injection (4 mg/100 mL) in single-dose bags. The product is indicated for treating Hypercalcemia of Malignancy, Multiple Myeloma, and Bone Metastases of Solid Tumors. According to IQVIA data, the product's US market sales were approximately USD 6.7 million for the twelve months ending November 2025. This approval strengthens Gland's sterile injectable portfolio in the key US market.
முக்கிய அம்சங்கள்
Received USFDA approval for Zoledronic Acid Injection, 4 mg/100 mL (0.04 mg/mL) Single-Dose BagsProduct is bioequivalent and therapeutically equivalent to the reference listed drug by InfoRLifeTarget indications include Hypercalcemia of Malignancy and Multiple MyelomaUS market sales for the product were approximately USD 6.7 million for the year ending November 2025
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive incremental addition to Gland's US portfolio, though the individual market size is modest. Monitor the company's ability to maintain its track record of USFDA approvals and market share gains in the generic injectables space.
Gland Pharma Q3 FY26 Revenue Up 22% to ₹1,695 Cr; Plans ₹2,000 Cr Capex Over 5 Years
Gland Pharma reported a strong Q3 FY26 with revenue growing 22% YoY to INR 16,954 million and adjusted EBITDA rising 25% to INR 4,490 million. The company announced a significant five-year capex plan of INR 2,000 crores focused on complex injectables, BFS, and ophthalmic lines. A major capacity expansion for cartridge fill and finish from 40 million to 140 million units is underway to target the GLP-1 and peptide markets. Management also noted a visible EBITDA turnaround at Cenexi and maintained a high R&D spend of 5.4% of revenue.
முக்கிய அம்சங்கள்
Revenue grew 22% YoY to INR 16,954 million in Q3 FY26, with 9M FY26 revenue up 12%.Adjusted EBITDA increased 25% YoY to INR 4,490 million, reflecting better operating leverage.Announced INR 2,000 crore capex over the next 5 years for brownfield expansions and CDMO contracts.Expanding cartridge fill and finish capacity by 250% from 40 million to 140 million units.Filed 9 ANDAs and launched 9 new products in the U.S. market during the quarter.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the ₹2,000 Cr capex plan and the ramp-up of the expanded cartridge capacity, which are critical for long-term value growth. The turnaround in Cenexi and strong EBITDA growth suggest improving operational efficiency and a positive outlook for the stock.
Gland Pharma Q3 FY26: Adj. PAT Surges 37% YoY to ₹2,797 Mn; Revenue Up 22%
Gland Pharma delivered a strong performance in Q3 FY26, with consolidated revenue growing 22% YoY to ₹16,954 Mn. The company's Adjusted PAT saw a significant jump of 37% YoY to ₹2,797 Mn, supported by a recovery in margins. Adjusted EBITDA margins improved to 26% from 23% in the previous quarter, reflecting better operational efficiency. The core base business remains the primary driver, contributing ₹11,790 Mn to revenue with a healthy 28% PAT margin.
முக்கிய அம்சங்கள்
Consolidated Revenue from operations grew 22% YoY and 14% QoQ to ₹16,954 MnAdjusted PAT increased 37% YoY to ₹2,797 Mn, with a sharp 52% sequential growthAdjusted EBITDA margin expanded to 26% in Q3 FY26 from 23% in Q2 FY26Base business revenue grew 16% YoY to ₹11,790 Mn with an Adjusted PAT of ₹3,274 MnR&D expenditure for the base business stood at ₹650 Mn, accounting for 5.5% of its revenue
👀 கவனிக்க வேண்டியவை
The strong double-digit growth in both top-line and bottom-line suggests a robust recovery in the injectable segment. Investors should maintain a positive outlook given the margin expansion and steady performance of the core business.
Gland Pharma reported a strong performance for the quarter ended December 31, 2025, with consolidated revenue from operations growing 22.5% year-on-year to ₹16,953.63 million. Sequentially, revenue increased by 14% from ₹14,868.75 million in the previous quarter, indicating robust business momentum. Profit before tax for the quarter stood at ₹3,864.74 million, showing resilience despite a rise in employee benefit expenses and material costs. The company also confirmed the reappointment of Grant Thornton Bharat LLP as internal auditors for the upcoming financial year.
முக்கிய அம்சங்கள்
Consolidated revenue from operations rose 22.5% YoY to ₹16,953.63 million in Q3 FY26.Quarter-on-quarter revenue growth was robust at 14% compared to ₹14,868.75 million in Q2 FY26.Total income for the nine-month period ended Dec 2025 reached ₹48,927.22 million versus ₹43,611.74 million YoY.Profit before tax for the quarter was ₹3,864.74 million, maintaining healthy operational margins.Grant Thornton Bharat LLP reappointed as Internal Auditors for the financial year 2026-27.
👀 கவனிக்க வேண்டியவை
The strong double-digit growth in revenue both YoY and QoQ suggests a recovery in core markets and effective scale-up. Investors should maintain a positive outlook while monitoring the impact of rising operational costs on net margins.
Gland Pharma has received USFDA approval for its ANDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The product is a generic equivalent to Alcon's Pataday Once Daily Relief, 0.7%, used for treating ocular itching from allergic conjunctivitis. This approval marks a significant addition to Gland's ophthalmic portfolio in the United States. The company continues to leverage its B2B model to expand its global footprint across 60 countries.
முக்கிய அம்சங்கள்
Approval received from USFDA for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC).Therapeutically equivalent to Alcon Laboratories' Pataday Once Daily Relief, 0.7%.Targeted at the treatment of ocular itching associated with allergic conjunctivitis.Strengthens Gland Pharma's position in the high-value US ophthalmic market.
👀 கவனிக்க வேண்டியவை
This approval is a positive catalyst for long-term growth in the US market; investors should maintain a positive outlook on the stock. Keep an eye on the launch timeline and potential market share gains in the OTC segment.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
